Published in JAMA Neurol on August 01, 2013
Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One (2013) 1.25
Tissue correction for GABA-edited MRS: Considerations of voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging (2015) 0.97
Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis. Ann Clin Transl Neurol (2014) 0.88
Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front Neurosci (2017) 0.86
Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis. Neurotherapeutics (2015) 0.83
Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. J Neural Transm (Vienna) (2015) 0.83
Edited (1) H magnetic resonance spectroscopy in vivo: Methods and metabolites. Magn Reson Med (2017) 0.81
Decreased auditory GABA+ concentrations in presbycusis demonstrated by edited magnetic resonance spectroscopy. Neuroimage (2014) 0.80
Frontal Gamma-Aminobutyric Acid Concentrations Are Associated With Cognitive Performance in Older Adults. Biol Psychiatry Cogn Neurosci Neuroimaging (2017) 0.80
Syphilis may be a confounding factor, not a causative agent, in syphilitic ALS. F1000Res (2016) 0.79
Normalizing data from GABA-edited MEGA-PRESS implementations at 3 Tesla. Magn Reson Imaging (2017) 0.76
Chronic inhibitory effect of riluzole on trophic factor production. Exp Neurol (2015) 0.76
Acute Exposure to Pacific Ciguatoxin Reduces Electroencephalogram Activity and Disrupts Neurotransmitter Metabolic Pathways in Motor Cortex. Mol Neurobiol (2016) 0.76
Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. Sci Rep (2016) 0.75
Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS. Sci Rep (2017) 0.75
Changes in the excitability of neocortical neurons in a mouse model of amyotrophic lateral sclerosis are not specific to corticospinal neurons and are modulated by advancing disease. J Neurosci (2017) 0.75
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 15.38
Amyotrophic lateral sclerosis. Lancet (2011) 5.86
Simultaneous in vivo spectral editing and water suppression. NMR Biomed (1998) 5.09
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 4.11
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol (2009) 3.73
Polarity-sensitive modulation of cortical neurotransmitters by transcranial stimulation. J Neurosci (2009) 3.25
In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med (2009) 2.27
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2007) 2.20
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn Reson Med (2007) 1.91
In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc (2011) 1.91
Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol (1998) 1.78
Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. Neurology (2012) 1.64
Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain (2011) 1.57
Magnetic resonance spectroscopy. J Neuroophthalmol (2005) 1.47
Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem (2010) 1.46
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol (2007) 1.41
The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2010) 1.30
Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport (1998) 1.27
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology (1999) 1.20
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS. J Neurol Neurosurg Psychiatry (2005) 1.16
Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve (1993) 1.14
MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2000) 1.14
Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol (2003) 1.08
Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci (2008) 1.08
Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS. Cereb Cortex (2010) 1.02
Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem (2000) 0.95
Amyotrophic lateral sclerosis: objective upper motor neuron markers. Curr Neurol Neurosci Rep (2002) 0.94
1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. J Neurol Sci (1999) 0.92
Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp Brain Res (2000) 0.92
Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol (2006) 0.92
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol (2006) 0.91
Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res (2004) 0.90
Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol (1994) 0.89
Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology (2002) 0.88
Riluzole: what it does to spinal and brainstem neurons and how it does it. Neuroscientist (2012) 0.85
Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol (2001) 0.84
Hyperexcitability and amyotrophic lateral sclerosis. Neurology (2012) 0.82
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med (2008) 4.62
Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care (2006) 3.47
Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death". Acad Med (2012) 3.43
Multi-parametric neuroimaging reproducibility: a 3-T resource study. Neuroimage (2010) 3.32
Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc Natl Acad Sci U S A (2009) 3.31
Re-examining the brain regions crucial for orchestrating speech articulation. Brain (2004) 3.23
Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care (2010) 3.20
Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med (2006) 2.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
Cerebral perfusion CT: technique and clinical applications. Radiology (2004) 2.91
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev (2004) 2.83
Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol (2009) 2.82
Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology (2013) 2.79
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Neural correlates of individual ratings of emotional salience: a trial-related fMRI study. Neuroimage (2004) 2.66
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Change in perfusion in acute nondominant hemisphere stroke may be better estimated by tests of hemispatial neglect than by the National Institutes of Health Stroke Scale. Stroke (2003) 2.61
Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57
Aging and the neural correlates of successful picture encoding: frontal activations compensate for decreased medial-temporal activity. J Cogn Neurosci (2005) 2.52
Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ Res (2008) 2.48
Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol (2007) 2.45
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet (2009) 2.23
Individual differences in subconscious motor control predicted by GABA concentration in SMA. Curr Biol (2010) 2.21
Diffusion tensor imaging in children and adolescents: reproducibility, hemispheric, and age-related differences. Neuroimage (2006) 2.21
Choosing Wisely: highest-cost tests in outpatient neurology. Ann Neurol (2013) 2.21
Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology (2008) 2.20
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J (2002) 2.18
Medial frontal cortex activity and loss-related responses to errors. J Neurosci (2006) 2.15
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol (2012) 1.99
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Theoretical and experimental investigation of the VASO contrast mechanism. Magn Reson Med (2006) 1.94
Stem cell technology for neurodegenerative diseases. Ann Neurol (2011) 1.93
Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn Reson Med (2007) 1.91
Childhood obstructive sleep apnea associates with neuropsychological deficits and neuronal brain injury. PLoS Med (2006) 1.91
In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc (2011) 1.91
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Microvascular complications of impaired glucose tolerance. Diabetes (2003) 1.88
Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells (2012) 1.87
Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology (2013) 1.86
Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol (2011) 1.85
Improving cancer screening adherence: using the "teachable moment" as a delivery setting for educational interventions. Am J Manag Care (2004) 1.84
Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth. J Biomed Mater Res A (2007) 1.83
Neural correlates of social and nonsocial emotions: An fMRI study. Neuroimage (2006) 1.82
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Impaired tactile processing in children with autism spectrum disorder. J Neurophysiol (2014) 1.81
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem (2008) 1.79
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
Mouse models of diabetic neuropathy. Neurobiol Dis (2007) 1.76
Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder. Biol Psychiatry (2005) 1.75
Anatomy of spatial attention: insights from perfusion imaging and hemispatial neglect in acute stroke. J Neurosci (2005) 1.75
Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J (2005) 1.75
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord (2012) 1.69
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A (2005) 1.65
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes (2009) 1.64
Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev (2011) 1.62
Regionally specific human GABA concentration correlates with tactile discrimination thresholds. J Neurosci (2011) 1.61
Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol (2009) 1.61
Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J (2009) 1.61
T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology (2004) 1.61
How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol (2010) 1.60
Restoring cerebral blood flow reveals neural regions critical for naming. J Neurosci (2006) 1.60
Human brain hemorrhage: quantification of perihematoma edema by use of diffusion-weighted MR imaging. AJNR Am J Neuroradiol (2002) 1.59
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J (2011) 1.58
Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. Neuroimage (2013) 1.58
Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder. J Psychiatry Neurosci (2012) 1.58
A functional neuroimaging study of motivation and executive function. Neuroimage (2004) 1.57
Gannet: A batch-processing tool for the quantitative analysis of gamma-aminobutyric acid–edited MR spectroscopy spectra. J Magn Reson Imaging (2013) 1.57
Neural dysregulation in posttraumatic stress disorder: evidence for disrupted equilibrium between salience and default mode brain networks. Psychosom Med (2012) 1.57
Ultrasonographic differentiation of malignant from benign breast lesions: a meta-analytic comparison of elasticity and BIRADS scoring. Breast Cancer Res Treat (2011) 1.56
Control of cell survival by IGF signaling pathways. Growth Horm IGF Res (2002) 1.56
In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med (2007) 1.55
More GABA, less distraction: a neurochemical predictor of motor decision speed. Nat Neurosci (2010) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. Eur Heart J (2012) 1.53
Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav (2011) 1.53
Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst (2009) 1.52
Fast 3D chemical exchange saturation transfer (CEST) imaging of the human brain. Magn Reson Med (2010) 1.52
Does fitness level modulate the cardiovascular hemodynamic response to exercise? J Appl Physiol (1985) (2006) 1.51
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev (2012) 1.51